MedPath

Evaluation of Salivary Gal-7, Gal-10 and MMP-9 Levels of Individuals With Different Periodontal Diseases

Not Applicable
Recruiting
Conditions
Periodontal Diseases
Interventions
Diagnostic Test: Saliva obtaining
Registration Number
NCT06186908
Lead Sponsor
Izmir Katip Celebi University
Brief Summary

The aim of this study is; detection of Galectin-10, Galectin-7, MMP-9 levels in saliva samples of periodontally healthy, gingivitis and periodontitis patients and the possible correlation between these values and clinical parameters of periodontal diseases. Materials and methods: Samples of saliva were obtained from 60 systemically healthy non-smoker individuals with periodontitis (P, n=20), gingivitis(G, n=20) and healthy periodontium (S, n=20). Full-mouth clinical periodontal measurements including probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were also recorded. Enzyme-linked immunosorbent assay (ELISA) was used to determine Galectin-10, Galectin-7 and MMP-9 levels in the biological samples.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Systemically healthy (The determination of healthy volunteers will be based on the statements of the patients in the anamnesis. No additional examinations will be made.)
  • At least twenty permanent teeth in the mouth
  • Non-smoker
  • No medication for continuous use
  • Those who have not used antibiotics, anti-inflammatory and systemic corticosteroid drugs in the last 6 months.
  • Not in pregnancy or lactation period.
  • For the periodontitis group that has not received periodontal treatment in the last 6 months
  • For the periodontitis group; According to the evaluation made in 6 regions of each tooth, individuals with 30% or more bleeding on probing area, at least 2 teeth not adjacent to each quarter jaw with a depth of 5 mm or more and 4 mm or more attachment loss, coronal 1/3 and more on radiography (horizontal and / or vertical) bone loss
  • For the gingivitis group; According to the evaluation made in 6 regions of each tooth, individuals with 10% or more bleeding on probing area, having a probing depth of less than 4mm and no attachment loss
  • For healthy group; According to the evaluation made in 6 regions of each tooth,individuals with less than 10% bleeding on probing area, having a probing depth less than 4mm and no loss of attachment were included in the study.
Exclusion Criteria
  • Any oral or systemic disease
  • Regularly using a systemic medication
  • During pregnancy or lactation
  • Received periodontal treatment within the last 6 months.
  • Those who received antibiotic, anti-inflammatory or systemic corticosteroid medication in the last 6 months
  • Smokers are not included in the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PeriodontitisSaliva obtainingFull-mouth clinical periodontal measurements recorded and saliva obtained.
GingivitisSaliva obtainingFull-mouth clinical periodontal measurements recorded and saliva obtained.
Healthy periodontiumSaliva obtainingFull-mouth clinical periodontal measurements recorded and saliva obtained.
Primary Outcome Measures
NameTimeMethod
The total amount of Gal-10 in saliva24 hours after taking the clinical measurements at the first visit

The total amount of Galectin-10 in saliva

The total amount of Gal-7 in saliva24 hours after taking the clinical measurements at the first visit

The total amount of Galectin-7 in saliva

The total amount of MMP-9 in saliva24 hours after taking the clinical measurements at the first visit

The total amount of Matrix metalloproteinase 9 in saliva

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Izmir Katip Çelebi University Department of Periodontology

🇹🇷

İzmir, Çiğli, Turkey

© Copyright 2025. All Rights Reserved by MedPath